In this study, we investigated the effects of anti-MDA5 antibodies on the clinical characteristics and prognosis of PM/DM patients by comparing and analyzing the basic information, clinical manifestations, laboratory findings, death, the occurrence of complications, and treatment in PM/DM patients in the positive and negative anti-MDA5 antibody groups [5–9]. This evidence concerns the gene IFIH1 and dermatomyositis.